ANIP ANI PHARMACEUTICALS INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1023024 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY25.9%
TTM net income YoY188.0%
TTM EPS YoY214.4%
Revenue 3-yr CAGR32.3%
Net income 3-yr CAGR105.9%
Margins
Gross margin61.1%
Operating margin16.0%
Net margin11.2%
FCF margin19.7%
EBITDA margin23.9%
Returns
ROE20.4%
ROA7.9%
ROIC (approx.)23.0%
Asset turnover0.70x
Leverage & solvency
Liabilities / assets59.4%
Debt / equity0.47x
Current ratio2.75x
Interest coverage5.44x
Cash quality & payout
Operating cash flow / net income1.96x
Accruals ratio-7.6%
Payout ratio0.0%
Capex / revenue2.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $883.37M | $614.38M | $486.82M | $316.38M | $216.14M |
| Cost of revenue | $341.31M | $250.21M | $181.51M | $138.78M | $100.61M |
| Gross profit | $542.06M | $364.17M | $305.30M | $177.60M | $115.53M |
| R&D expense | $51.66M | $44.58M | $34.29M | $22.32M | $11.37M |
| SG&A expense | $317.75M | $249.64M | $161.70M | $124.04M | $84.29M |
| Operating income | $111.09M | $584,000 | $46.97M | -$35.28M | -$39.79M |
| Interest expense | $32.56M | $33.63M | $35.63M | $28.51M | $11.95M |
| Pretax income | $95.79M | -$22.21M | $19.87M | -$62.66M | -$56.06M |
| Income tax | $17.45M | -$3.69M | $1.09M | -$14.77M | -$13.46M |
| Net income | $78.34M | -$18.52M | $18.78M | -$47.90M | -$42.60M |
| EBITDA | $202.51M | $68.31M | $106.76M | $21.69M | $7.46M |
| EPS (basic) | 3.50 | -1.04 | 0.86 | -3.05 | -3.40 |
| EPS (diluted) | 3.32 | -1.04 | 0.85 | -3.05 | -3.40 |
| Weighted avg. shares (diluted) | 21.23M | 19.32M | 18.19M | 16.26M | 12.60M |
| Balance sheet | |||||
| Cash & equivalents | $285.58M | $144.86M | $221.12M | $48.23M | $100.30M |
| Receivables | $281.08M | $221.73M | $162.08M | $165.44M | $128.53M |
| Inventory | $143.07M | $136.78M | $111.20M | $105.36M | $81.69M |
| Current assets | $753.12M | $528.46M | $519.82M | $344.26M | $321.77M |
| PP&E, net | $62.48M | $56.86M | $44.59M | $43.25M | $52.67M |
| Goodwill | $62.48M | $59.99M | $28.22M | $28.22M | $27.89M |
| Intangibles | $479.53M | $541.83M | $209.01M | $251.63M | $294.12M |
| Total assets | $1.44B | $1.28B | $904.42M | $760.09M | $771.60M |
| Current liabilities | $278.11M | $194.45M | $145.48M | $99.44M | $87.54M |
| Short-term debt | $17.27M | $9.17M | $850,000 | $850,000 | $850,000 |
| Long-term debt | $291.84M | $309.11M | $284.82M | $285.67M | $286.52M |
| Total debt | $309.11M | $318.28M | $285.67M | $286.52M | $287.37M |
| Total liabilities | $899.65M | $855.94M | $446.82M | $421.55M | $412.86M |
| Shareholders' equity | $540.72M | $403.68M | $432.75M | $313.69M | $333.89M |
| Net debt | $23.52M | $173.42M | $64.55M | $238.29M | $187.07M |
| Shares outstanding | 22.49M | 21.11M | — | — | — |
| Cash flow statement | |||||
| Operating cash flow | $185.22M | $64.02M | $118.96M | -$31.20M | $3.32M |
| Capital expenditure | $13.84M | $16.24M | $8.87M | $8.88M | $2.56M |
| Free cash flow | $171.39M | $47.78M | $110.09M | -$40.08M | $765,000 |
| Investing cash flow | -$34.32M | -$404.72M | -$18.51M | -$15.74M | -$105.48M |
| Financing cash flow | -$9.94M | $264.94M | $67.44M | -$5.13M | $194.59M |
| Depreciation & amortization | $91.42M | $67.73M | $59.79M | $56.97M | $47.25M |
| Stock-based compensation | $37.93M | $29.34M | $20.65M | $14.60M | $10.49M |
| Dividends paid | $1.16M | $1.62M | $1.62M | $1.62M | $190,000 |
| Share buybacks | $12.21M | $10.96M | $4.99M | $1.96M | $890,000 |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.